Torrent Pharmaceuticals shares gained 2.02% to trade at ₹4,999.00 on Tuesday, continuing its strong financial performance trajectory. The stock remains a constituent of the NIFTY NEXT 50 index and has demonstrated consistent upward momentum, reflecting investor confidence in the company's financial resilience and strategic corporate decisions.
The company delivered impressive quarterly performance for Q1 FY27, with consolidated revenue reaching ₹4,921 crore, representing a substantial 54.85% increase from ₹3,178 crore reported in Q1 FY26. Consolidated net profit demonstrated positive momentum, rising by 3.28% to ₹566 crore in Q1 FY27 from ₹548 crore in the corresponding quarter of the previous year. However, Earnings Per Share (EPS) for the quarter-ending June 2026 was reported at ₹14.87, compared to ₹16.19 in Q1 FY26. The company's quarterly performance shows consistent growth with revenue increasing from ₹3,178 crore in June 2025 to ₹4,921 crore in June 2026, while net profit rose from ₹548 crore to ₹566 crore over the same period.
On an annual consolidated basis, Torrent Pharmaceuticals reported revenue of ₹13,979.73 crore for the year-ending March 2026, marking a significant 21.39% growth from ₹11,516.09 crore in FY25. The company's consolidated net profit climbed to ₹2,138.18 crore in FY26, representing an 11.88% increase from ₹1,911.25 crore in FY25. Basic EPS for FY26 was ₹63.92, reflecting a 13.20% increase from ₹56.47 in FY25, while Return on Networth/Equity (ROE) improved to 25.78% from 25.17% in the previous year. The company's financial metrics show consistent improvement with gross profit margin at 31.93% and operating margin at 23.93% for FY26, compared to 32.51% and 25.61% respectively in FY25.
Analysis of financial ratios for FY26 indicates a P/E ratio of 66.02x and P/B ratio of 17.03x as of March 2026, as reported by Moneycontrol. The company's Debt to Equity ratio stands at 1.76x and Interest Coverage Ratio is 11.59x for FY26. Cash flow from operating activities significantly increased to ₹3,022 crore in March 2026 from ₹2,585 crore in March 2025, while cash flow from investing activities recorded a substantial outflow of ₹12,712 crore in March 2026, compared to an outflow of ₹540 crore in March 2025. The company's balance sheet shows total assets of ₹44,311 crore as of March 2026, with fixed assets of ₹29,842 crore and total liabilities of ₹44,311 crore, reflecting the company's substantial asset base and debt position.
The company has announced a final dividend of ₹9.00 per share (180%) on May 22, 2026, with an effective date of May 29, 2026, and an interim dividend of ₹29.00 per share (580%) on February 4, 2026, with an effective date of February 18, 2026, as reported by Moneycontrol. Torrent Pharmaceuticals has also issued bonus shares in the past, with the most recent being a 1:1 bonus announced on July 8, 2022, and underwent a stock split on February 20, 2006, changing the face value from ₹10 to ₹5. The company recently announced an Investor Meet under Regulation 30 of SEBI regulations on August 11, 2026, along with an ESG Rating intimation on the same day. These corporate actions reflect the company's commitment to rewarding shareholders while maintaining its position as a closely watched stock within the pharmaceutical sector.
